Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — ZIOPHARM Oncology — BIO CEO & Investor Conference 2014
22 slides from Alaunos Therapeutics's conference presentation, Feb 10, 2014
Slide 1: The Future of Cancer Therapy
Exhibit 99.1 The Future of Cancer Therapy BIO CEO & Investor Conference February 2014 www.ziopharm.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statement
Slide 3: ZIOPHARM Today
ZIOPHARM Today Clinical-stage cancer immunotherapy company Focus on treatment through DNA expression and control Phase 1/2 program targeting melanoma, breast cancer and glioma Intrexon partnership enabling potential paradigm shift New INDs through 2015 exploring multigenic approach to cancer treatme
Slide 4: Why Focus on DNA-Based Medicine?
Why Focus on DNA-Based Medicine? DNA synthesis and delivery enable: creation of new therapies which target cancer cells precise control of biologic concentration and dosing better therapeutic index through controlled protein delivery and cellular targeting economically feasible approach to combinati
Slide 5: Intrexon Collaboration: Leveraging Our Assets
Intrexon Collaboration: Leveraging Our Assets ZIOP: translational medicine and oncology drug development XON: synthetic biology platform enabling DNA delivery and control Exclusive channel partner agreement in all human cancer: ZIOP responsible for product development and commercialization XON respo
Slide 6: We Have the Tools to Treat Cancer Better
We Have the Tools to Treat Cancer Better Effectors mAb scFv Protein Metabolic Intracellular RNA toxin Ligand Enzyme decoy Cells T Cell B Cell Macrophage NK cell Treg Other immune Epithelial Endothelial cells Immune Cells Non-immune Cells Direct tumor lysis Pro-apoptosis Anti-tumor Complement ADCC Ne
Slide 7: The Power of Intrexon’s RheoSwitch® Technology
The Power of Intrexon’s RheoSwitch® Technology Controlled Expression and Delivery of Therapeutic Proteins with RheoSwitch®: This is the most advanced clinical method to turn genes on and off Gene Expression High Potency Monogenic/Multigenic RheoSwitch® Dose-control Orally activated biologic on/off s
Slide 8: IL-12 Production is Modulated by Veledimex in HT 1080 Cells
IL-12 Production is Modulated by Veledimex (Activator Ligand) in HT 1080 Cells ON 19 OFF OFF -1 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 Time after viral transduction (hours) mIL-12 expression(ng/ml medium/6hrs)
Slide 9: Veledimex Tightly and Precisely Controls the Expression of IL-12ß mRNA in the Tumor
Veledimex Tightly and Precisely Controls the Expression of IL-12ß mRNA in the Tumor ON OFF OFF 0.1 Baseline Maximum D1-D7 7 Days Post-treatment 100 mg 160 mg Veledimex Dose n=7 Tumor mRNA (mRNA/1e6 vp)
Slide 10: Cytotoxic T Cells & Memory T Cells Significantly Increase in Tumors Following Ad-RTS-IL-12
Cytotoxic T Cells & Memory T Cells (TILs) Significantly Increase in Tumors Following Ad-RTS-IL-12 Treatment Off On CD8+ CD45RO+ Images were obtained using an Aperio ScanScope XT whole-slide imager and digitized at 20x.
Slide 11: Systemic Immune Activity: patterns of anti-tumor response
Systemic Immune Activity: patterns of anti-tumor response %Change from baseline lesion size 0 -25 -50 -75 Patient# 1 2 3
Slide 12: Peak Serum IL-12 Concentration
Peak Serum IL-12 Concentration 11137 ± 3530 rIL-12 = recombinant IL-12 hIL-12 = Ad RTS IL-12 27 ± 14 rIL-12* hIL-12 Concentration of IL-12 (pg/mL) *Atkins, MB et al Clin Cancer Res 1997;3:409-417
Slide 13: Clinical Observations to Date
Clinical Observations to Date We can control gene expression to achieve a desirable immune response High expression of IL-12 mRNA in tumors, tightly controlled by veledimex dose Increased tumor infiltrating lymphocytes observed in the tumor microenvironment, suggesting multiple favorable biologic ef
Slide 14: Glioblastoma Multiforme: IL-12 Preclinical Activity
Glioblastoma Multiforme: IL-12 Preclinical Activity Kaplan Meier Survival in GL261 Orthotopic Syngeneic Mouse Glioma Model Percent survival 0 10 20 30 40 50 60 70 80 Time (Days) No Treatment DC-no vector DC-RTS-IL12 (MOI 10000) Ad-RTS-IL12 (5x109) AL chow DC-RTS-IL12 (MOI 10000) + AL Ad-RTS-IL12 (5x
Slide 15: Significant Market Potential for Ad-RTS-IL-12
Significant Market Potential for Ad-RTS-IL-12 Incidence Breast Cancer 234,580 Glioma 18,000 Melanoma 76,690
Slide 16: IL-12 Program Plans
IL-12 Program Plans Melanoma Phase 2 combination study with SOC FPI 1H 2014 Preliminary data YE 2014 Breast Cancer Phase 2 combination study with SOC FPI 1H 2014 Preliminary data 1H 2015 GBM Phase 1 dose-escalation study FPI 1H 2014 Preliminary data YE 2014
Slide 17: A Growing Oncology Portfolio
A Growing Oncology Portfolio Compound Pre Clinical Phase 1 Phase 2 Ad-RTS-IL-12 IND Melanoma Breast GBM Cell-based programs Cell signal targeting Multigenic platforms Immunotherapy programs
Slide 18: Potential DNA Combination Therapies: Future INDs
Potential DNA Combination Therapies: Future INDs Human mesenchymal stem cells genetically modified with genes that program the body to destroy cancer Multigenic therapeutic antibodies such as single chain versions of Hercept in® and Erbitux® Embedded cellular bioreactors to deliver multiple proteins
Slide 19: Upcoming Milestones
Upcoming Milestones Program Milestone Timing IL-12 Phase 2 breast cancer study data 2014 Phase 2 advanced melanoma study data 2014 Initiate Phase 1/2 glioblastoma multiforme study 1H 2014 Initiate Phase 2 melanoma combo study 1H 2014 Initiate Phase 2 breast cancer combo study 1H 2014 New Indications
Slide 20: Financial Highlights
Financial Highlights Approx. 100 million shares outstanding (pro forma) Approx. $77.4 million in cash and investments (pro forma) No debt Development partner/top shareholder: Intrexon Corp. (NYSE: XON)
Slide 21: ZIOPHARM Oncology
ZIOPHARM Oncology Phase 2 program advancing in breast cancer and melanoma Glioblastoma results due in 2014 Preparing INDs for new studies in 2014 and 2015 Exploring multigenic combination therapies to improve standards of care
Slide 22: The Future of Cancer Therapy
The Future of Cancer Therapy NASDAQ: ZIOP www.ziopharm.com
ZIOPHARM Oncology — BIO CEO & Investor Conference 2014 on 6ix